⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17340413 | 1.00 | — | — | |
| SCHEMBL3504811 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL19642660 | 0.97 | — | — | |
| Trifluoroacetic Acid SCHEMBL26696008 | 0.84 | GRB2 (0.32) | — | |
| Bromide SCHEMBL1086994 | 0.81 | ALOX15 (0.37) | — | |
| SCHEMBL27588313 | 0.79 | ALOX15 (0.35) | — | |
| SCHEMBL29143209 | 0.78 | — | — | |
| SCHEMBL6432607 | 0.77 | — | — | |
| SCHEMBL6546177 | 0.77 | — | — | |
| SCHEMBL288980 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114667144-A | Use of FAK inhibitors for the treatment of NRAS mutated tumors | 应世生物科技(南京)有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-122094961-A | DNA-dependent protein kinase inhibitors and compositions based on 5, 6-core silacycle and their use in gene editing | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122094952-A | Pyrazolopyridine-based DNA-dependent protein kinase inhibitors and compositions and their use in gene editing | — | 2026-05-26 | — | — | CN | disclosed |
| CN-114401960-B | Glue degradation agent and using method thereof | NOVARTIS AG (CH) | 2026-05-26 | — | — | CN | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250361205-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | ENSYSCE BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12384744-B2 | Enzyme-cleavable methadone prodrugs and methods of use thereof | Ensysce Biosciences Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120118088-A | Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-113072546-B | Five-membered heteroaromatic derivative and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120025333-A | Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof | 广东东阳光药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-110240557-B | Pyrrolidine amide derivatives and use thereof | 广东东阳光药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-110845402-B | Pyridine methylene piperazine derivatives and uses thereof | 广东东阳光药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115989027-A | Combination of methionine aminopeptidase 2 inhibitor and VEGFR/VEGF inhibitor | 默克专利股份公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | 3I, LP | 2022-09-15 | — | — | US | disclosed |
| WO-2022192197-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022162312-A1 | PEPTIDES AND USES THEREOF | SCHWEIGHOFFER FABIEN (FR) | 2022-08-04 | — | — | WO | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114667144-A | Use of FAK inhibitors for the treatment of NRAS mutated tumors | 应世生物科技(南京)有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2015170775-A1 | SUBSTITUTED AZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES | 日産化学工業株式会社 | 2015-11-12 | — | — | WO | disclosed |